Yung-Chih Wang, PhD, MBA

Yung-Chih Wang, PhD, MBA

Dr. Wang is responsible for HUYABIO’s corporate development in China. With over 25 years industry experience in global pharmaceutical research and development, alliances establishment, and business development, she leverages her experience to optimize business strategy, increase operational efficiency, and enhance cross-border cooperation. Before joining HUYABIO, Yung-Chih led projects at Ferring Pharmaceuticals in drug target identification-validation, drug screening, key collaborations of discovery programs, and strategic plan implementation.

HUYABIO International Announces Initiation of HBI-3000 Phase 2 Trial

HUYABIO International Announces Initiation of HBI-3000 Phase 2 Trial

San Diego, CA, USA – June 14, 2022 – HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).

Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with dosing AF patients in our Phase 2 trial of HBI-3000.

HUYABIO International Announces Completion of HBI-3000 Phase 1 Trial and FDA Approval to Proceed With Dose Escalation in Phase 2

HUYABIO International Announces Completion of HBI-3000 Phase 1 Trial and FDA Approval to Proceed With Dose Escalation in Phase 2

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with the strong CYP2D6 inhibitor, paroxetine

San Diego, CA, USA – May 17, 2022 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical

Clinical stage drug is the fifth asset in the growing pipeline of HUYABIO’s oncology products

San Diego, CA, USA – December 2, 2021 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the KRAS inhibitor, JMKX1899, from Shanghai Jemincare Pharmaceutical Co.,

HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in Japan

HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in Japan

This is the second indication for Hiyasta® in Japan following adult T-cell leukemia/lymphoma (ATLL)

SAN DIEGO, November 30, 2021 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals

Ex-China rights to the novel drug expands HUYABIO’s growing oncology pipeline

San Diego, CA, USA – November 9, 2021 – HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, announced today it had licensed exclusive worldwide ex-China rights to the Wee1 inhibitor from Shanghai Pharma, the second largest pharma group in China with annual sales of over $30 billion.

HUYABIO International Announces Initiation of Phase 2 Atrial Fibrillation Trial

HUYABIO International Announces Initiation of Phase 2 Atrial Fibrillation Trial

First patient dosed in trial investigating cardioversion of recent-onset atrial fibrillation

San Diego, CA, USA – November 2, 2021 – HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug for cardioversion of atrial fibrillation (AF) at Wellington Regional Hospital in Wellington, New Zealand.

HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors

HUYABIO Announces FDA Clearance to Initiate a Phase 1 Trial of SHP2 Inhibitor in Patients with KRAS and EGFR Mutated Tumors

San Diego, CA, USA – October 28, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study. The authorization to proceed enables the first testing in patients for whom this novel SHP2 inhibitor might show clinical benefit. 

HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan

HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan

SAN DIEGO, CA, USA – October 19, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the product launch in Japan for Hiyasta® tablets to treat relapsed and/or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL).

Japanese patients with relapsed and/or refractory R/R ATLL have very poor prognosis.

HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma

HUYABIO Announces First Patient Treated in a Pivotal Study of HBI-8000 Combined with Opdivo® (nivolumab) in Patients with Advanced Melanoma

San Diego, CA, USA – September 21, 2021 – HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the first patient treated in a pivotal trial designed to measure the safety and efficacy of HBI-8000 combined with Bristol Myers Squibb’s anti-PD-1, antibody Opdivo® (nivolumab), in patients with unresectable or metastatic melanoma.